biote Corp. (BTMD)

Market Cap	141.36M
Revenue (ttm)	199.07M
Net Income (ttm)	31.31M
Shares Out	45.82M
EPS (ttm)	0.88
PE Ratio	3.51
Forward PE	12.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,405
Open	2.950
Previous Close	2.890
Day's Range	2.950 - 3.170
52-Week Range	2.760 - 6.980
Beta	1.21
Analysts	Buy
Price Target	6.00 (+94.49%)
Earnings Date	Aug 6, 2025

About BTMD

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice m...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 2012
• Employees: 217
• Stock Exchange: NASDAQ
• Ticker Symbol: BTMD
• Website: https://www.biote.com

Financial Performance

In 2024, biote's revenue was $197.19 million, an increase of 6.38% compared to the previous year's $185.36 million. Earnings were $3.16 million, a decrease of -4.79%.

Analyst Forecast

According to 2 analysts, the average rating for BTMD stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 94.49% from the latest price.

Price Target

$6.0

(94.49% upside)

Analyst Consensus: Buy